Outlook Therapeutics (OTLK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Jan, 2026Voting matters and shareholder proposals
Election of three directors: Faisal G. Sukthian, Yezan Haddadin, and Kurt J. Hilzinger, with board recommending a vote for each.
Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026.
Non-binding advisory vote on the compensation of named executive officers, with board recommending approval.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders will vote on a non-binding advisory resolution regarding executive officer compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Outlook Therapeutics
- Net loss of $23.1M, negative revenue, and liquidity risks as US approval remains uncertain.OTLK
Q1 202617 Feb 2026 - EU/UK approvals achieved; 2025 launches planned, but going concern risk persists.OTLK
Q3 20241 Feb 2026 - Annual meeting to vote on directors, auditor ratification, and executive compensation advisory.OTLK
Proxy Filing26 Jan 2026 - First EU/UK approvals and payer-driven pricing set stage for 2025 U.S. launch in $16B market.OTLK
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Ophthalmic bevacizumab nears US and EU launches, targeting regulatory exclusivity and payer value.OTLK
Virtual Investor Closing Bell Series20 Jan 2026 - ONS-5010 matched ranibizumab in vision gains and retinal thickness reduction in phase 3.OTLK
Study Update9 Jan 2026 - First European sales drive revenue growth as net loss narrows; U.S. FDA decision pending.OTLK
Q4 202519 Dec 2025 - First-in-class ophthalmic bevacizumab for wet AMD launches in Europe; US approval pending.OTLK
Registration Filing16 Dec 2025 - Advancing first approved ophthalmic bevacizumab for retina, with new funding and EU/UK launches.OTLK
Registration Filing16 Dec 2025